Article citationsMore >>

Zhao Q, Li F, Song P, Zhou X, An Z, Mei J, Shao J, Li H, Wang X, Guo X, Zhai Y. Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience. Cancer Commun (Lond). 2019 Sep 27; 39(1): 51.

has been cited by the following article:

Article

Immunoglobulin D Multiple Myeloma, a More Aggressive Subtype

1Department of Internal medicine, Beaumont Hospital, Dearborn, MI

2Division of Hematology & Oncology, Internal Medicine Department, Beaumont Hospital, Dearborn, MI


American Journal of Medical Case Reports. 2021, Vol. 9 No. 5, 301-304
DOI: 10.12691/ajmcr-9-5-11
Copyright © 2021 Science and Education Publishing

Cite this paper:
Eman EL-Sawalhy, Najlaa Al-Sudani, Wehbi Hnayni, Shahina Patel. Immunoglobulin D Multiple Myeloma, a More Aggressive Subtype. American Journal of Medical Case Reports. 2021; 9(5):301-304. doi: 10.12691/ajmcr-9-5-11.

Correspondence to: Eman  EL-Sawalhy, Department of Internal medicine, Beaumont Hospital, Dearborn, MI. Email: Eman.elsawalhy@beaumont.org

Abstract

Immunoglobulin D (IgD) multiple Myeloma (MM) is a very rare subtype of myeloma. It accounts for only 1-2% of all MM patients. It is associated with a rapidly progressive disease and poorer outcomes compared with other MM subtypes. In this case report, we present a case of a sixty-year-old man who presented to our hospital with fatigue, anemia, thrombocytopenia, and acute renal failure. His bone marrow biopsy during admission showed 75.9% of plasma cells with significant light chain burden. He was also found to have severe immunoglobulin deficiency along with a lambda to kappa ratio was <0.01. The diagnosis of IgD MM was established, and he was started on CyBorD (Bortezomib, cyclophosphamide, and dexamethasone). Our patient also required hemodialysis for his kidney failure.

Keywords